ELEVATE Blend (Semax / Selank / BPC-157 / KPV): What It Is, Where to Get It Prescribed, and What It Costs

ELEVATE is not a single molecule. It is four independently studied peptides — Semax, Selank, BPC-157 and KPV — dissolved together in one sterile multi-dose vial by a compounding pharmacy. Each has its own research literature, its own described mechanism and its own regulatory file at the FDA. The name is a brand name for the combination; it does not appear in any journal. That shapes everything on this page: "does ELEVATE work" has to be broken into four questions, because the combination itself has never been studied as a combination.

The rationale prescribers give is that the brain and the gut are treated as one system. Semax and Selank are the two neuropeptides, one described around attention and neurotrophic signalling, the other around anxiety and GABA tone. BPC-157 and KPV are the two gut components, one described around protecting the intestinal lining, the other around damping the inflammatory signalling that keeps a gut complaint going. A person whose complaint spans both gets all four in one injection rather than four.

The proportions are worth noticing. BPC-157 and KPV are 20 of the 30 mg in the vial, so by mass ELEVATE is two-thirds a gut preparation. Each 0.25 mL dose delivers 0.25 mg Semax, 0.25 mg Selank, 0.5 mg BPC-157 and 0.5 mg KPV — half the Semax and Selank that the single-agent vials deliver per dose. The ratio is fixed by the pharmacy's formulation and cannot be adjusted per component, which is the genuine trade-off of any blend.

It is not a stimulant and does not work like one, and it is not a substitute for prescribed ADHD treatment. It is not a benzodiazepine, even though the Russian trials compared Selank with that class. It is not a treatment for a diagnosed psychiatric condition, a diagnosed inflammatory bowel disease or a structural gut problem — those belong with the specialist treating them. It is not a hormone, a steroid or a growth hormone secretagogue. And it is not a nootropic in the sense of something shown to sharpen thinking in healthy adults: that trial has not been run for any of the four.

Semax is a heptapeptide: positions 4 to 7 of adrenocorticotropic hormone with a Pro-Gly-Pro tail added to slow breakdown. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, is a registered medicine in Russia as nasal drops, and has been used in Russian neurology for ischaemic stroke and chronic cerebrovascular disease since the 1990s. The literature describes it as devoid of the corticotropic activity of its parent hormone, so it is not expected to raise cortisol.

The most cited mechanism is a 2006 paper in Brain Research, which reported that Semax increased BDNF protein and TrkB receptor phosphorylation in the rat hippocampus, alongside more conditioned avoidance responses in the treated animals. A 2010 paper in Cellular and Molecular Neurobiology reported the same neurotrophin signalling switched on selectively in ischaemic tissue in rats with a blocked cerebral artery. Both are rat findings. A fuller treatment is on the Semax page.

Selank is also a heptapeptide: tuftsin, a natural four-amino-acid immune-signalling fragment of immunoglobulin G, with the same stabilising tail. It comes from the same Russian institute, with the Zakusov Institute of Pharmacology, and is registered in Russia as an intranasal prescription anxiolytic. Nearly all of the published research comes from the originating groups.

Two mechanisms are described. A 2018 paper in Protein and Peptide Letters reported, in rat brain-cell membranes, that Selank changed GABA binding in the manner of a positive allosteric modulator of the GABA-A receptor — the receptor family benzodiazepines act on, by a different binding pattern. A 2001 paper in the Bulletin of Experimental Biology and Medicine reported that it inhibited the enzymes that degrade leu-enkephalin in human plasma; a 2008 clinical paper measured the same marker rising in patients during treatment, which makes this the one mechanism with a human correlate. A fuller treatment is on the Selank page.

BPC-157 is a fifteen-amino-acid partial sequence of a protein originally isolated from human gastric juice, and the largest body of its research concerns protection of the gastrointestinal lining in animal models — against NSAID- and alcohol-induced damage, and in inflammatory bowel models. Animal work describes it activating the VEGFR2 receptor and nitric-oxide signalling, the axis the body uses to grow new blood vessels into healing tissue, and a 2014 paper in Molecules reported it increasing growth hormone receptor expression in cultured tendon fibroblasts.

One line of BPC-157 research explains why it sits in this blend rather than a repair one. A 2016 review in Current Neuropharmacology and a 2022 review in Neural Regeneration Research, both from the Zagreb group that has produced most of the BPC-157 literature, summarise rat work describing the peptide acting on the brain-gut axis — on dopamine and serotonin systems, on behaviour in stress models, and on gut function at the same time. That is the described basis for pairing it with two neuropeptides. It is rat work from a single research group: a framing, not a treatment claim. A fuller treatment is on the BPC-157 page.

KPV is the last three amino acids — lysine, proline, valine — of alpha-melanocyte-stimulating hormone. Alpha-MSH drives pigmentation through the melanocortin-1 receptor and separately has anti-inflammatory effects; the isolated tripeptide is reported to keep the second and lose the first, which is why KPV does not darken skin. A 2008 review in Endocrine Reviews sets out that literature.

The most specific mechanism is in the gut. A 2008 paper in Gastroenterology reported that KPV is carried into intestinal epithelial cells by PepT1, the transporter the gut lining uses to absorb small peptides from food, and that it reduced NF-kB activation and cytokine output in cells and in mouse colitis. A 2008 paper in Inflammatory Bowel Diseases reported reduced weight loss and histological inflammation in two mouse colitis models. In this blend, the logic is that inflammation that never resolves is the commonest reason a gut complaint stays unsettled. A fuller treatment is on the KPV page.

The map below is the clinical rationale for the blend. It is a rationale, not a finding — no study has confirmed that the four act together when injected together, and no study has measured the combination against any one component.

The cognitive label attached to ELEVATE rests on rat studies. For Semax, the 2006 Brain Research work tied the BDNF finding to a conditioned-avoidance measure, and a 2024 paper in the European Journal of Pharmacology reported that daily low-dose Semax counteracted the loss of sucrose preference and the fall in hippocampal BDNF in male rats under chronic unpredictable stress. For Selank, mouse work from 2002 reported an anxiolytic effect in an open-field test in one strain and none in another, and a 2019 rat study reported prevention of alcohol-related memory disturbance alongside a change in hippocampal BDNF. These are mechanism findings in animals. No trial has measured attention, memory or mood in healthy adults on either peptide.

Semax has the larger human literature of the four, and it is in patients with brain injury rather than healthy people. A 1997 controlled clinical study in the Korsakov Journal of Neurology and Psychiatry compared 30 acute ischaemic stroke patients given intranasal Semax alongside standard care with 80 conventionally treated patients and reported faster regression of deficits; a 2018 trial from the same group in 110 stroke patients reported higher plasma BDNF and better Barthel Index scores in the Semax subgroups; a 2005 evaluation of 187 patients with chronic cerebrovascular insufficiency reported clinical improvement and good tolerability. All used the intranasal product registered in Russia, and the FDA's July 2026 review could not use most of them because complete English translations were not supplied.

Selank has controlled human trials — Russian, small, compared against an active benzodiazepine rather than placebo, and not described as randomised or blinded in the published abstracts. The 2008 Korsakov Journal paper treated 62 patients with generalised anxiety disorder or neurasthenia with Selank or medazepam and reported a similar anxiolytic effect, with Selank described as mildly activating rather than sedating; a 2014 paper compared it with phenazepam in 60 patients and reported an effect persisting about a week after the last dose. A 2021 review in the Journal of Clinical Pharmacology characterised Selank as poorly studied outside its country of origin, which is fair.

This is where the animal evidence in ELEVATE is deepest. BPC-157's original and largest literature is gastrointestinal: rat work describing protection against NSAID- and alcohol-induced gastric damage and improvement in inflammatory bowel models. KPV's evidence is the 2008 Gastroenterology and Inflammatory Bowel Diseases work above, plus a 2017 paper in Molecular Therapy that delivered KPV in colon-targeted nanoparticles and reported reduced colitis in mice at a far lower dose — a formulation study, not something a compounding pharmacy supplies. Most of the KPV gut work gave the peptide orally, because of the PepT1 transporter, and the subcutaneous route has not been compared.

This is the honest part, and the part worth understanding before starting.

There are no randomised controlled trials of ELEVATE, or of any four-peptide combination of these components, in humans. The blend has never been studied as a blend. Evidence is per component, and it is uneven:

• Semax has Russian clinical studies in stroke, chronic cerebrovascular disease and optic nerve disease, several controlled and some over a hundred patients, nearly all intranasal. There are no randomised, placebo-controlled trials in English-language journals, and no trial for attention or memory in healthy adults.
• Selank has small Russian comparator trials against benzodiazepines, 60 to 70 patients each, intranasal, none placebo-controlled and none replicated outside Russia.
• BPC-157 has early-phase human work for inflammatory bowel indications and substantial prescribing experience. There are no large randomised controlled trials in humans.
• KPV has no human trials of any kind. Its evidence is cell work, including human intestinal cell lines, and mouse models.

Much of medicine rests on mechanism plus clinical experience, and that is the basis physicians prescribe ELEVATE on. But the accurate framing is "described in preclinical research and in Russian clinical series, and used clinically," not "proven in people" — and for the cognitive and mood side, not studied in healthy people at all.

• That four peptides together do more than any one alone. No study has compared the blend with its components.
• Any effect on focus, memory, mood or anxiety in healthy adults. No trial has measured that for Semax or Selank, by any route.
• Equivalence between the intranasal route of the Russian studies and subcutaneous injection. The FDA found no published literature on subcutaneous Semax at all.
• An effect size or a timeline in humans. Timelines given by prescribers are clinical experience, not trial endpoints.
• Long-term safety over years of continuous use, which is part of why a physician reviews each refill.
• Efficacy for any condition as an FDA-approved treatment. Neither ELEVATE nor any component is approved for anything in the United States.

Semax was placed in Category 2 of the FDA's 503A bulk drug substances list in 2023 — the category for nominated substances with identified safety concerns — over a theoretical immunogenicity concern from aggregation and peptide-related impurities. It was among the twelve peptides the FDA removed from Category 2 in April 2026, and the FDA's safety-risks page, current as of 22 April 2026, now lists it only among substances "nominated but withdrawn."

On 24 July 2026 the Pharmacy Compounding Advisory Committee considered Semax (free base and acetate) for the 503A Bulks List, for the nominated uses of cerebral ischaemia, migraine and trigeminal neuralgia, and voted 8–5, with one abstention, to recommend adding it. The FDA's own briefing document had recommended against listing: it judged the substance not well characterised, could not rule out immunogenicity for the injectable route, found "insufficient evidence to support the effectiveness" for the nominated uses on the English-language material available, and "was unable to find literature that discussed administration via subcutaneous injection." The committee voted the other way.

Selank has a different history from the peptides that made the news in 2026. Selank acetate, listed by the FDA as "Selank acetate (TP-7)," was placed in Category 2 on 29 September 2023. On 27 September 2024 the FDA removed it, recording that the nominator had intended to nominate a different substance — a withdrawn nomination, not a decision on the science. The FDA's safety-risks page, current as of 22 April 2026, lists it among substances "nominated but withdrawn"; the 503A category list updated 14 May 2026 does not carry it in any category; it was not on the July 2026 advisory committee agenda, and it is not among the five peptides the committee will consider before the end of February 2027.

Both were placed in Category 2 in 2023 and both were among the April 2026 removals; the FDA's page now lists each as "nominated but withdrawn." On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8–6, with one abstention in each case, to recommend adding BPC-157 and KPV — each as the free base and the acetate — to the 503A Bulks List. BPC-157 was evaluated for ulcerative colitis, KPV for wound healing and inflammatory conditions. FDA's own scientists had recommended against inclusion for each, citing insufficient safety, efficacy and characterisation data; the committee voted the other way.

As of September 2026: none of the four components sits in Category 1, 2 or 3 of the 503A list updated 14 May 2026, and none is restricted. Three — Semax, BPC-157 and KPV — have been recommended for the positive list by the advisory committee, over the objection of FDA staff, and await the agency's final determination through rulemaking. Selank has never been reviewed. All four remain legal for a physician to prescribe and a state-licensed pharmacy to compound. None is an FDA-approved drug product, and compounded medications never are — they are prepared by a licensed pharmacy to a physician's prescription, not approved as manufactured products. See are peptides FDA approved.

Most people report nothing dramatic. Injection-site tenderness is the most commonly reported observation. Some describe mild alertness on dosing days, some the opposite, a flat or tired feeling in the first days; both are described as settling. On the gut side, some describe background discomfort being quieter. Noticing nothing at all in this window is normal and is not a sign the course is not working.

This is the window one vial covers on a weekday schedule, and where prescribers most often describe any change on either side: less reactivity to stress, less mental fatigue late in the day, a gut that is less of a daily presence. These are background changes rather than events, which makes them easy to overattribute. A simple daily log — sleep, mood, gut symptoms — is more useful than memory, and it is what your physician will want when deciding on a second vial.

Whether a second vial is prescribed depends on what the first one changed. A physician who sees nothing after a full vial will usually reconsider rather than repeat, and may move to a single component to find out which, if any, is doing the work. The 2014 Selank trial reported the anxiolytic effect persisting about a week after the last dose; there is no equivalent human data for the other three.

No withdrawal syndrome and no rebound are described in the published work for any component, and none of the four suppresses a system that then has to restart. Whether any benefit persists is unknown, and depends on what was driving the complaint to begin with.

The directions are written in millilitres and in insulin-syringe units because that is what you can actually read off the barrel. 0.25 mL is 25 units on a U-100 syringe; the number is printed on your medication. Because the four are in fixed proportion, every dose delivers the same split — 0.25 mg Semax, 0.25 mg Selank, 0.5 mg BPC-157 and 0.5 mg KPV — and you cannot take more of one and less of another. If your directions and syringe markings appear to disagree, ask before dosing.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. There is no "near the problem" logic with this blend: two components are aimed at the brain and two at the gut, and the route is systemic either way. Morning is the usual direction, because some people describe restlessness if Semax is taken late in the day.

20 doses at once daily, Monday through Friday, is four weeks, which is why refills run on a 28-day cycle. The weekday-only pattern is a prescribing convention rather than a schedule from any trial: it keeps total exposure modest and builds in a regular break, given that long-term data does not exist for any component. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating runs from first puncture and is on the label; a multi-peptide vial is not something to keep past it. Do not freeze it and do not shake it.

The two-peptide preparation is the neuropeptide-only version. It omits BPC-157 and KPV, and delivers twice the Semax and Selank per dose that ELEVATE does. If focus and stress are the whole picture, it is the more targeted prescription and a physician may reasonably prefer it; ELEVATE exists for people who describe the gut as part of the same problem.

Same neuropeptide pair, different partners. The SYNAPSE blend combines Semax and Selank with MOTS-c and tesamorelin, for a complaint that straddles cognition and cellular energy or metabolism; ELEVATE combines them with BPC-157 and KPV, for one that straddles cognition and the gut. SYNAPSE's tesamorelin component usually calls for bloodwork; ELEVATE does not routinely.

Same gut base, different additions. The FORTIFY blend keeps BPC-157 and KPV and adds thymosin alpha-1 and LL-37, the immune pair, where ELEVATE adds the neuropeptide pair. If the question is immune function, FORTIFY is the conversation; if it is head and gut together, ELEVATE is. A gut complaint on its own narrows to BPC-157 alone. There is no pepti Pen for ELEVATE; it is a vial and syringe only.